Pure Global
NCT06397781

Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients

Boston Children's Hospital·Phase 4·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Atopic Dermatitis
Drug/Device/Intervention
Skin Cleanser Combination No.1
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Boston Children's Hospital
Timeline & enrollment
Phase
Phase 4
Start date
May 01, 2024
End date
Jul 01, 2028
Enrollment
50 participants
Primary outcome

Severity Scoring of Atopic Dermatitis Index

Summary

Our hypothesis is that S. aureus skin decolonization in atopic dermatitis reduces disease
 severity and favorably alters the function and gene expression of epidermal and immune skin
 cells that contribute to disease severity.

ICD-10 classifications
Atopic dermatitisAtopic dermatitis, unspecifiedOther atopic dermatitisAcute atopic conjunctivitisAllergic contact dermatitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06397781
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06397781 through Pure Global AI's free database. This Phase 4 trial is sponsored by Boston Children's Hospital and is currently Not yet recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.